Literature DB >> 23393330

Regulation of the proliferation of colon cancer cells by compounds that affect glycolysis, including 3-bromopyruvate, 2-deoxyglucose and biguanides.

Michael A Lea1, Mehreen S Qureshi, Michael Buxhoeveden, Nicolette Gengel, Jessica Kleinschmit, Charles Desbordes.   

Abstract

In previous studies performed by our group, we observed that 2-deoxyglucose blocked the acidification of the medium used for culture of colon cancer cells caused by incubation with biguanides and it had an additive inhibitory effect on growth. In the present work, we found that 3-bromopyruvate can also prevent the lowering of pH caused by biguanide treatment. 3-Bromopyruvate inhibited colonic cancer cell proliferation, but the effect was not always additive to that of biguanides and an additive effect was more notable in combined treatment with 3-bromopyruvate and 2-deoxyglucose. The induction of alkaline phosphatase activity by butyrate was not consistently affected by combination with other agents that modified glucose metabolism. The drug combinations that were examined inhibited proliferation of wild-type and p53-null cells and affected colonic cancer lines with different growth rates.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23393330      PMCID: PMC3805264     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  18 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage.

Authors:  F Bunz; A Dutriaux; C Lengauer; T Waldman; S Zhou; J P Brown; J M Sedivy; K W Kinzler; B Vogelstein
Journal:  Science       Date:  1998-11-20       Impact factor: 47.728

3.  Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells.

Authors:  Issam Ben Sahra; Kathiane Laurent; Sandy Giuliano; Frédéric Larbret; Gilles Ponzio; Pierre Gounon; Yannick Le Marchand-Brustel; Sophie Giorgetti-Peraldi; Mireille Cormont; Corine Bertolotto; Marcel Deckert; Patrick Auberger; Jean-François Tanti; Frédéric Bost
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

Review 4.  3-bromopyruvate: a new targeted antiglycolytic agent and a promise for cancer therapy.

Authors:  S Ganapathy-Kanniappan; M Vali; R Kunjithapatham; M Buijs; L H Syed; P P Rao; S Ota; B K Kwak; R Loffroy; J F Geschwind
Journal:  Curr Pharm Biotechnol       Date:  2010-08       Impact factor: 2.837

5.  Sulforhodamine B colorimetric assay for cytotoxicity screening.

Authors:  Vanicha Vichai; Kanyawim Kirtikara
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

6.  Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase.

Authors:  Y H Ko; P L Pedersen; J F Geschwind
Journal:  Cancer Lett       Date:  2001-11-08       Impact factor: 8.679

7.  The pyruvic acid analog 3-bromopyruvate interferes with the tetrazolium reagent MTS in the evaluation of cytotoxicity.

Authors:  Shanmugasundaram Ganapathy-Kanniappan; Jean-Francois H Geschwind; Rani Kunjithapatham; Manon Buijs; Labiq H Syed; Pramod P Rao; Shinichi Ota; Mustafa Vali
Journal:  Assay Drug Dev Technol       Date:  2010-04       Impact factor: 1.738

8.  Targets of 3-bromopyruvate, a new, energy depleting, anticancer agent.

Authors:  Paolo Dell'Antone
Journal:  Med Chem       Date:  2009-11       Impact factor: 2.745

9.  Induction of differentiation of colon cancer cells by combined inhibition of kinases and histone deacetylase.

Authors:  Michael A Lea; Chinwe Ibeh; Neel Shah; Mary P Moyer
Journal:  Anticancer Res       Date:  2007 Mar-Apr       Impact factor: 2.480

10.  Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing.

Authors:  Y P Keepers; P E Pizao; G J Peters; J van Ark-Otte; B Winograd; H M Pinedo
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

View more
  5 in total

1.  Growth inhibition of colon cancer cells by compounds affecting AMPK activity.

Authors:  Michael A Lea; Jacob Pourat; Rupali Patel; Charles desBordes
Journal:  World J Gastrointest Oncol       Date:  2014-07-15

Review 2.  Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication.

Authors:  Minjong Lee; Jung-Hwan Yoon
Journal:  World J Biol Chem       Date:  2015-08-26

3.  Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer.

Authors:  Ji-Hye Park; Young-Heon Kim; Eun Hyeh Park; Sun-Joo Lee; Hyewon Kim; Areumnuri Kim; Seung Bum Lee; Sehwan Shim; Hyosun Jang; Jae Kyung Myung; Sunhoo Park; Su-Jae Lee; Min Jung Kim
Journal:  Cancer Sci       Date:  2019-08-02       Impact factor: 6.716

Review 4.  Metabolic Targeting of Cancer Stem Cells.

Authors:  Anna Mukha; Anna Dubrovska
Journal:  Front Oncol       Date:  2020-12-22       Impact factor: 6.244

5.  The effect of 3-bromopyruvate on human colorectal cancer cells is dependent on glucose concentration but not hexokinase II expression.

Authors:  Nelson Ho; Jodi Morrison; Andreza Silva; Brenda L Coomber
Journal:  Biosci Rep       Date:  2016-01-06       Impact factor: 3.840

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.